Physician profile
Robert O Wilson
NPI 1649354465
$1,476.57
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $471 · 2021: $367.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $567.50 | 2019-2021 | |
| Daiichi Sankyo INC. | $176.73 | 2019-2020 | |
| Aspira Women'S Health INC | $133.12 | 2019 | |
| Pfizer INC. | $110.37 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $86.12 | 2019-2020 | |
| Allergan, INC. | $72.81 | 2019-2020 | |
| Hologic Sales and Service, LLC | $69.85 | 2019-2021 | |
| Therapeuticsmd, INC. | $63.41 | 2019-2020 | |
| Bard Access Systems, INC. | $52.32 | 2019 | |
| Lupin INC. | $45.96 | 2019-2020 | |
| Myovant Sciences INC. | $45.12 | 2021 | |
| Roche Diagnostics Corporation | $23.38 | 2019 | |
| Coloplast Corp | $17.28 | 2020 | |
| Agile Therapeutics, INC. | $12.60 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.